share_log

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jin Medical International | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

中进医疗 | 6-K:外国发行人报告
美股SEC公告 ·  03/29 16:15

Moomoo AI 已提取核心信息

Jin Medical International Ltd. has received a favorable decision from the Nasdaq Hearings Panel, granting the company's request for continued listing on The Nasdaq Stock Market. This decision comes after the company was previously notified of non-compliance with Nasdaq's Listing Rule 5550(a)(3) due to having fewer than the required 300 public holders. Despite regaining compliance with this rule, Jin Medical International still faced a deficiency for not filing its annual report on Form 20-F for the fiscal year ended September 30, 2023. The Panel has allowed the company to remain listed, with the condition that it files the overdue annual report by May 20, 2024. The company has confirmed that it is working to prepare and file the report within the granted extension period.
Jin Medical International Ltd. has received a favorable decision from the Nasdaq Hearings Panel, granting the company's request for continued listing on The Nasdaq Stock Market. This decision comes after the company was previously notified of non-compliance with Nasdaq's Listing Rule 5550(a)(3) due to having fewer than the required 300 public holders. Despite regaining compliance with this rule, Jin Medical International still faced a deficiency for not filing its annual report on Form 20-F for the fiscal year ended September 30, 2023. The Panel has allowed the company to remain listed, with the condition that it files the overdue annual report by May 20, 2024. The company has confirmed that it is working to prepare and file the report within the granted extension period.
Jin Medical International Ltd.已收到纳斯达克听证小组的赞成决定,批准了该公司继续在纳斯达克股票市场上市的请求。该决定是在该公司此前被告知由于公众持有人少于所需的300名而未遵守纳斯达克上市规则5550(a)(3)之后做出的。尽管恢复了对该规定的遵守,但金医疗国际仍因未提交截至2023年9月30日的财政年度的20-F表年度报告而面临缺陷。该小组允许该公司继续上市,条件是该公司必须在2024年5月20日之前提交逾期的年度报告。该公司已确认正在努力在规定的延期内准备和提交报告。
Jin Medical International Ltd.已收到纳斯达克听证小组的赞成决定,批准了该公司继续在纳斯达克股票市场上市的请求。该决定是在该公司此前被告知由于公众持有人少于所需的300名而未遵守纳斯达克上市规则5550(a)(3)之后做出的。尽管恢复了对该规定的遵守,但金医疗国际仍因未提交截至2023年9月30日的财政年度的20-F表年度报告而面临缺陷。该小组允许该公司继续上市,条件是该公司必须在2024年5月20日之前提交逾期的年度报告。该公司已确认正在努力在规定的延期内准备和提交报告。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息